Brief: Roche Presents New Phase Iii One-Year Data For Vamikibart In Uveitic Macular Edema
10/10/2026 22:42
BRIEF-Roche Presents New Phase Iii One-Year Data For Vamikibart In Uveitic Macular Edema Oct 10 (Reuters) - Roche Holding AG ROPC.S:
ROCHE PRESENTS NEW PHASE III ONE-YEAR DATA FOR VAMIKIBART IN UVEITIC MACULAR EDEMA (UME), A SERIOUS CAUSE OF VISION LOSS
ROCHE HOLDING AG - VAMIKIBART DEMONSTRATES SUSTAINED VISION IMPROVEMENTS AND REDUCED MACULAR THICKNESS AT 52 WEEKS
Source text: ID:nGNE5j1QJw
Further company coverage: ROPC.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey